7 Biotechnology Stocks to Buy Now

Advertisement

Seven biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

ArQule, Inc. (ARQL) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. ArQule is a biotechnology company that is engaged in the research and development of cancer therapeutics. In Portfolio Grader’s specific subcategory of Earnings Revisions, ARQL also gets an A. For more information, get Portfolio Grader’s complete analysis of ARQL stock.

La Jolla Pharmaceutical Company (LJPC) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

This week, Incyte Corporation’s (INCY) ratings are up from a C last week to a B. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.

This week, Ambit Biosciences Corp. (AMBI) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Progenics Pharmaceuticals, Inc. (PGNX) improves from a C to a B rating this week. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Celladon Corporation’s (CLDN) ratings are looking better this week, moving up to an A from last week’s B. For more information, get Portfolio Grader’s complete analysis of CLDN stock.

Bioline RX Ltd Sponsored ADR (BLRX) gets a higher grade this week, advancing from a C last week to a B. BioLineRx, a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of BLRX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/07/7-biotechnology-stocks-to-buy-now-arql-ljpc-incy/.

©2024 InvestorPlace Media, LLC